Tobias M. Hohl: Overview

Print
Print

All people encounter, inhale, and ingest fungi on a daily basis. Although only several hundred of the estimated five million species of fungi worldwide cause disease in humans, advances in medical technologies and the global AIDS pandemic have dramatically increased our susceptibility to fungal disease.

In cancer and bone marrow transplant patients, the filamentous mold Aspergillus fumigatus and the commensal fungus Candida albicans represent significant causes of infection-related morbidity and mortality. At present, no fungal vaccines have been licensed for clinical use, and contemporary antifungal therapies for systemic mycoses are often ineffective in patients with disease- or treatment-associated damage to the immune system. My laboratory’s research centers on the theme of fungal pathogenesis and immunology, with a primary focus on deciphering the molecular and cellular events required for effective antifungal immunity.